Filter your search
Infectious DiseaseX
Infectious disease tests are one of the most dynamic spaces in the in vitro diagnostics (IVD) industry. Global market growth is a product of new disease threats as well as the introduction and clinical acceptance of routine screening procedures. The diversified market space promotes demand for novel diagnostic technologies such as PCR-alternative molecular amplification methods, next-generation sequencing (NGS), and mass spectrometry. The $17 billion+ global infectious disease diagnostics market also includes larger established segments in immunoassays and ID/AST.
- $2,995.00 – $5,995.00This Kalorama Information report, Point of Care Infectious Disease Diagnostic Testing provides market sizing and forecasts for the following disease areas Influenza STD HIV Hepatitis Malaria C. difficile E. coli H. pylori Home Test/OTC Others Point of care testing market features competitors that are large major concerns as well as newer entrants and specialist players. […]March 22, 2018$3,360.00 – $6,720.00Molecular point-of-care (POC) diagnostics are able to improve the sensitivity and specificity of existing near-patient and rapid tests and also expand the diagnostic capabilities at points of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts in the developing world.bThe Market and Potential for Molecular Point of Care Diagnostics […]February 26, 2016$3,500.00 – $7,000.00The World Market for Infectious Disease Diagnostic Tests World Market for Infectious Disease Tests provides detailed market estimates and forecasts for four major areas of infectious disease testing, including identification and antibiotic susceptibility testing, immunoassays, molecular testing and blood screening and subsegments within. POC and home testing markets for infectious disease are also provided. Sales […]November 1, 2015The World Health Organization has identified a group of diseases that are the world’s most pressing health problems. This represents an opportunity for test manufacturers, particularly in POC testing. Because of their ability to deliver fast results at the point of care, rapid testing is a focus area of healthcare providers and payors in infectious […]October 1, 2011$150.00 – $300.00A hospital-acquired infection (HAI)is a new infection that develops in a patient during hospitalization. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a nosocomial infection (or […]July 1, 2011$250.00 – $1,600.00The outbreak of H1N1 (swine flu) highlighted the public health importance of improved testing techniques and providing market opportunities for manufacturers of diagnostic tests and other products related to the disease. These conclusions and others appear in a new report released from Kalorama Information: Swine Flu Market Alert by Kalorama’s lead analyst, Shara Rosen. Regardless […]May 1, 2009$1,500.00 – $7,000.00Test services, once the norm in the diagnostics industry, then abandoned for reagent sales, are now making a comeback. IVD companies have established cGMP and CLIA-registered labs by which they offer their proprietary tests to physicians, hospitals and reference labs. These tests are outside the oversight of the traditional FDA and CE Mark test commercialization […]August 1, 2008$995.00 – $1,990.00Currently, the largest market application segment for molecular diagnostics is that for infectious disease testing. The segment is expected to grow at an annual rate between 7% and 8% over the next few years will present some excellent market opportunites for molecular diagnostic competitors. This summary report, extracted from Kalorama Information’s U.S. Market for Molecular […]October 1, 2004
